ARCA Biopharma (NASDAQ:ABIO) has submitted an Investigational New Drug application under the Coronavirus Treatment Acceleration Program (CTAP) to evaluate AB201 for the treatment of patients hospitalized with COVID-19.
Pending FDA feedback, ARCA anticipates to initiate the Phase 2b portion of a sequential Phase 2b/3 of AB201 as early as the fourth quarter of this year.
AB201 is a small recombinant protein being developed as a potential treatment for RNA virus- associated disease, initially focusing on COVID-19.
Last month, the company concluded talks with the FDA to clarify a development path for the drug candidate.
https://seekingalpha.com/news/3615643-arca-biopharma-files-to-commence-ab201-study-for-covidminus-19
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.